Selecta Biosciences Receives $38,000,000 Series E Round

  • Feed Type
  • Date
    9/8/2015
  • Company Name
    Selecta Biosciences
  • Mailing Address
    480 Arsenal St. Building One Watertown, MA 02472 USA
  • Company Description
    Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.
  • Website
    http://www.selectabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $38,000,000
  • Transaction Round
    Series E
  • Proceeds Purposes
    Proceeds from the financing will be used to advance multiple product candidates from Selecta’s Synthetic Vaccine Particle (SVP) platform, which creates antigen-specific immunotherapeutics, with priority implementation of the clinical program for Selecta’s lead immunotherapeutic candidate, SEL-212, which is designed to be the first non-immunogenic biologic therapy for gout.
  • M&A Terms
  • Venture Investor
    OrbiMed
  • Venture Investor
    Sanofi-Genzyme BioVentures
  • Venture Investor
    Ridgeback Capital
  • Venture Investor
    Osage Partners
  • Venture Investor
    AJU IB Investment
  • Venture Investor
    Undisclosed

Trending on Xconomy